Smruthi Organics Limited BSE Scrip Code:

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Smruthi Organics Limited BSE Scrip Code: 590046"

Transcription

1 Smruthi Organics Limited BSE Scrip Code: Pharmaceuticals September 21, 2012 Equity Statistics Current Market Price Rs Week High / Low Rs / 155 Market Capitalisation Rs. crores 83.2 Free Float Rs. crores 29.7 Dividend Yield % 1.4 One Year Regression Beta Times 0.4 BSE Volumes Trend - Average = 1.65 Thousand in '000s Relative Returns Returns (%) 1M 3M 6M 1Yr Absolute 2% 36% 26% 17% Relative to Sensex -3% 23% 15% 2% Shareholding Pattern 100% Sensex Smruthi Business Summary Smruthi Organics Limited (Smruthi) manufactures Active Pharmaceutical Ingredients (APIs) and intermediates and Specialty Chemicals from its plants in Sholapur, which are certified by United States Food and Drug Administration (US FDA) and European Good Manufacturing Practice (EU-GMP). The major APIs manufactured by the company are Metformin Hydrochloride (used for treatment of type II diabetes), Norfloxacin (for treatment of urinary tract infections) and Amlodipine (an anti hypertensive drug). The major export markets for the company are USA and European Union, which contributed about 22% of the operating revenues in FY12 (Financial year (FY) refers to the period between April 1 and March 31). Smruthi benefits from the presence in the contract manufacturing space. The capacity expansion is carried out by the company for one of its products, Metformin Hydrochloride which is expected to be operational by H1FY13. Smruthi faces competition from Chinese manufacturers which might impact its pricing and profitability. Going ahead, the company plans to expand its contract manufacturing business, and diversify its export markets to Latin America and South East Asia. Smruthi is currently trading at 7.98 times its FY12 EPS and 2.33 times its FY12 adjusted Book Value. Board of directors Person Role Qualification E. Purushotham CMD M.Sc. (Organic Chemistry) E. Swapnil ED B.S (Chemical Engineering), MBA E. Vaishnavi NED B.A. Dr. Nagender Yerram NED (I) M.Sc., Ph.D Dr. K. Rama Swamy NED MD (Physician) J.H. Ranade NED (I) B.Com, LLB, FCS, MBA Source: AR and CARE Research Note: CMD: Chairman and Managing Director, ED: Executive Director, NED: Non Executive Director, I - Independent 50% 0% Sep '11 Dec '11 Mar '12 Jun '12 Promoter DII FII Others 1 Initiative of the BSE Investors Protection Fund

2 Background Smruthi Organic Limited, manufacturer of Active Pharmaceutical Ingredient (APIs) was founded in 1989 by Mr Eaga Purushotham. The company manufactures API, fine chemicals and specialty chemicals, all in the same plant. The APIs manufactured by Smruthi are used for treatment of urinary tract infection, diabetes, hyper-tension, heart failure etc. Smruthi has two manufacturing plants in Sholapur. During FY11, the company received approval from US-FDA for both its units to manufacture APIs (the first approval for one plant was received in FY07). The company has taken an expansion project for manufacturing of Metformin Hydrochloride, expanding the capacity of production by 3,000MTPA to capitalize on the market demand for the product. Business overview Smruthi derives its revenues from contract manufacturing and self-manufactured product sales. Revenues from contract manufacturing contributed to 68% of total revenues in FY12 (52% in FY11) growing at a higher rate than product sales. The major cost for Smruthi is raw material cost, contributing to 85% of the total expenditure incurred by the company in FY12. Geographically, the domestic market continues to be the key contributor to the operating revenues of Smruthi Organics, with 78% of the total revenues being earned from the Indian market. However, the export market grew at a higher rate (59% in FY12 y-o-y), though on a small base; when compared to the domestic market (23% y-o-y). Strengths and growth drivers US-FDA and EU-GMP approved manufacturing facilities Stable increase in sales with a CAGR of 37.84% during FY08-FY12. Expansion into new geographical areas and incremental sales of Metformin Hydrochloride are expected to contribute to the growth in revenue. Risk and concerns Economic downturn in Europe, key export market for the company Competition from Chinese manufacturers Future strategy and expansion plans Smruthi Organic has its focus on expanding the markets of existing products in the short term to medium term. With expansion in capacity of Metformin Hydrochloride, the company is planning to target new customers. Expansion of export markets to Latin America and South East Asia Industry outlook The Indian Pharmaceutical Industry includes formulations, bulk drugs (APIs) and Contract Research and Manufacturing Services (CRAMS). The Pharmaceutical companies are increasingly looking at outsourcing manufacturing and R&D activities, thereby driving the growth of the CRAMS industry. API manufacturing is the largest contributor to the outsourcing market with 55% share. The pharmaceutical industry is regulated on patents, quality and price. Between FY05 and FY10, the Bulk Drug industry grew at a CAGR (Compounded Annual Growth Rate) of about 15%. The industry has been growing at a fast rate on the back of production of quality products at affordable prices. The export demand of the industry remains intact on account of increasing number of companies looking to outsource production of bulk drugs and higher penetration. The higher number of US-FDA approvals to manufacturing units in India when compared to the other global players gives an advantage to the Indian companies. The Drug Master Filings (DMH) has also been increasing over the period. Government maintains considerable control over the manufacturing of bulk drugs along with some regulations on pricing and other safety aspects. The major competitor for the Indian bulk drug manufacturers are the Chinese companies whose technological advancement enable them to supply bulk drugs at low cost. This affects the margins of the Indian companies. 2 Initiative of the BSE Investors Protection Fund

3 Peer comparison Year ended March 31, 2012 Income statement (Rs. Crore) Smruthi Anuh Neuland Sequent Total income Net sales EBITDA Ordinary PAT Adjusted PAT (5.0) Per share data (Rs.) Adjusted BVPS Diluted EPS Growth (Y-o-Y) (%) Growth in total income Growth in net sales Growth in EBITDA NM NM Growth in adjusted PAT NM NM Growth in EPS* NM NM Profitability ratio (%) EBITDA margin Adjusted PAT margin Valuation ratios (Times) Price/EPS (P/E) Price/Book value (P/BV) Enterprise value (EV)/EBITDA Note: Anuh - Anuh Pharma Ltd., Neuland: Neuland Laboratories Ltd., Sequent: Sequent Sceintific Ltd. Quarterly financials Quarter ended June 30, 2012 Income statement (Rs. crore) Q1FY13 Q4FY12 Q3FY12 Q2FY12 Q1FY12 Total income Net sales EBITDA Ordinary PAT Adjusted PAT Growth (Q-o-Q) (%) Growth in net sales (12.2) Profitability ratio (%) EBITDA margin Adjusted PAT margin Initiative of the BSE Investors Protection Fund

4 Financial analysis Smruthi s Revenue from operations has grown at a CAGR of 37.84% from FY08 to FY12, with revenue of Rs.206 cr in FY12. Though the sales registered a growth of 31.7% in FY12 y-o-y, the growth in PAT was 10% y-o-y on account of increased operational expenditure and higher interest costs. EBITDA margin fell by 120 bps in FY12 y-o-y on account of higher proportion of revenue from contract manufacturing. The total debt was Rs.32.3 crore as compared to net worth of Rs35.8 crore The company has paid a dividend of Rs.3 per share for FY12, resulting in a dividend yield of 1.4% at the current market price of Rs per share. Annual financial statistics FY08 FY09 FY10 FY11 FY12 Income statement (Rs. crore) Total income Net sales EBITDA Depreciation and amortisation EBIT Interest PBT Ordinary PAT Adjusted PAT Balance sheet (Rs. crore) Adjusted networth Total debt Cash and bank Investments Net fixed assets (incl. CWIP) Net current assets (excl. cash, cash equivalents) Per share data (Rs.) Adjusted BVPS Diluted EPS* DPS Growth (Y-o-Y) (%) Growth in total income Growth in net sales Growth in EBITDA Growth in adjusted PAT NM Growth in EPS* NM Key financial ratio EBITDA margin (%) Adjusted PAT margin (%) RoCE (%) RoE (%) Gross debt - equity (times) Net debt - equity (times) Interest coverage (times) Current ratio (times) Inventory days Receivable days Financial year (FY) refers to the period from April, 1 to March, Initiative of the BSE Investors Protection Fund

5 DISCLOSURES Each member of the team involved in the preparation of this grading report, hereby affirms that there exists no conflict of interest that can bias the grading recommendation of the company. This report has been sponsored by the BSE Investors Protection Fund. DISCLAIMER CARE Research, a division of Credit Analysis & REsearch Limited [CARE] has taken utmost care to ensure accuracy and objectivity while developing this report based on information available in public domain or from sources considered reliable. However, neither the accuracy nor completeness of information contained in this report is guaranteed. Opinions expressed herein are our current opinions as on the date of this report. Nothing in this report can be construed as either investment or any other advice or any solicitation, whatsoever. The subscriber / user assumes the entire risk of any use made of this report or data herein. CARE specifically states that it or any of its divisions or employees do not have any financial liabilities whatsoever to the subscribers / users of this report. This report is for personal information only of the authorised recipient in India only. This report or part of it should not be reproduced or redistributed or communicated directly or indirectly in any form to any other person or published or copied for any purpose. PUBLISHED BY CARE Research is an independent research division of CARE Ratings, a full-service rating company. CARE Research is involved in preparing detailed industry research reports with 5-year demand and 2-year profitability outlook on the industry besides providing comprehensive trend analysis and the current state of the industry. CARE Research also offers research that is customized to client requirements. Credit Analysis & REsearch Ltd. (CARE) is a full service rating company that offers a wide range of rating and grading services across sectors. CARE has an unparallel depth of expertise. CARE Ratings methodologies are in line with the best international practices. Head Office: 4th Floor Godrej Coliseum, Off Eastern Express Highway, Somaiya Hospital Road, Sion East, Mumbai Tel: Fax: Regional Offices: New Delhi Kolkata Ahmedabad Bangalore Hyderabad Chennai Pune Published on behalf of The Stock Exchange Investors' Protection Fund First Floor, P J Towers, Dalal Street, Mumbai. Tel: /34

Mazda Limited BSE Scrip Code:

Mazda Limited BSE Scrip Code: Mazda Limited BSE Scrip Code: 523792 Industrial Machinery September 14, 2012 Equity Statistics Current Market Price Rs. 91.2 52 Week High / Low Rs. 106.0/70.25 Market Capitalisation Rs. crores 38.8 Free

More information

Company Overview. Financial Performance

Company Overview. Financial Performance Jan/15 Feb/15 Mar/15 Apr/15 May/15 Jun/15 Jul/15 Aug/15 Sep/15 Oct/15 Nov/15 Dec/15 SPS Finquest Ltd CMP: 84.60 January 13, 2015 Stock Details BSE code 538402 BSE ID SPS Face value ( ) 10 No of shares

More information

BUY RSWM LTD SYNOPSIS. CMP 292.20 Target Price 336.00. SEPTEMBER 1 st 2015. Result Update(PARENT BASIS): Q1 FY16

BUY RSWM LTD SYNOPSIS. CMP 292.20 Target Price 336.00. SEPTEMBER 1 st 2015. Result Update(PARENT BASIS): Q1 FY16 BUY CMP 292.20 Target Price 336.00 RSWM LTD Result Update(PARENT BASIS): Q1 FY16 SEPTEMBER 1 st 2015 ISIN: INE611A01016 Index Details Stock Data Sector Textiles BSE Code 500350 Face Value 10.00 52wk. High

More information

PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)

PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%) BUY CMP 196.40 Target Price 225.00 STYLAM INDUSTRIES LIMITED Result Update (PARENT BASIS): Q2 FY16 DECEMBER 16 th. 2015 ISIN: INE239C01012 12 th h, 2013 Index Details Stock Data Sector Plastic Products

More information

Gujarat State Petronet Ltd. INR 135

Gujarat State Petronet Ltd. INR 135 Jan-15 Mar-15 May-15 Jul-15 Sep-15 Nov-15 Jan-16 India Equity Institutional Research Oil & Gas RESULT UPDATE Gujarat State Petronet Ltd. INR 135 Growth in volumes to propel earnings Accumulate Gujarat

More information

BUY. KELLTON TECH SOLUTIONS LTD Result Update (CONSOLIDATED): Q1 FY16. CMP 226.50 Target Price 260.00. JANUARY 9 th 2015 SYNOPSIS ISIN: INE164B01022

BUY. KELLTON TECH SOLUTIONS LTD Result Update (CONSOLIDATED): Q1 FY16. CMP 226.50 Target Price 260.00. JANUARY 9 th 2015 SYNOPSIS ISIN: INE164B01022 BUY CMP 226.50 Target Price 260.00 KELLTON TECH SOLUTIONS LTD Result Update (CONSOLIDATED): Q1 FY16 JANUARY 9 th 2015 ISIN: INE164B01022 Index Details Stock Data Sector IT Software Products BSE Code 519602

More information

BUY. ECLERX SERVICES LIMITED (CONSOLIDATED) Result Update: Q1 FY16. CMP 1677.00 Target Price 1880.00. SEPTEMBER 2 nd, 2015 SYNOPSIS ISIN: INE738I01010

BUY. ECLERX SERVICES LIMITED (CONSOLIDATED) Result Update: Q1 FY16. CMP 1677.00 Target Price 1880.00. SEPTEMBER 2 nd, 2015 SYNOPSIS ISIN: INE738I01010 BUY CMP 1677.00 Target Price 1880.00 ECLERX SERVICES LIMITED (CONSOLIDATED) Result Update: Q1 FY16 SEPTEMBER 2 nd, 2015 ISIN: INE738I01010 Index Details Stock Data Sector IT & ITes BSE Code 532927 Face

More information

Sphere Global Services Limited

Sphere Global Services Limited Sphere Global Services Limited Date: 13 th January, 216 Stock Performance Details Shareholding Details September 215 Current Price : ` 3.95^ Face Value : ` 1 per share 52 wk High / Low : ` 9.35 / 31.1

More information

Avon Organics Limited

Avon Organics Limited 15 October 2012 CMP: Rs.29.2 Industry: Commodity chemicals BSE group/index: B Promoters Arch Pharmalabs Limited Year of incorporation 1993 Corporate office Avon Organics Limited 541/A, Arch House, Marol

More information

PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)

PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%) BUY CMP 170.30 Target Price 196.00 GEOMETRIC LTD Result Update (CONSOLIDATED): Q2 FY16 DECEMBER 17 th 2015 ISIN: INE797A01021 12 th h, 2013 Index Details Stock Data Sector IT Consulting & Software BSE

More information

Flexituff International Ltd. (FIL)

Flexituff International Ltd. (FIL) s $CompanyN ame$ Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 (Wholly owned subsidiary of Bank of Baroda) Q2FY16 Result Review BUY Flexituff International Ltd. (FIL)

More information

PI Industries. 2QFY16 Result Review HOLD. Custom synthesis restricted 2Q revenue growth ; maintain HOLD. Sector: AGRI

PI Industries. 2QFY16 Result Review HOLD. Custom synthesis restricted 2Q revenue growth ; maintain HOLD. Sector: AGRI $Com panyname$ Oct-14 Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 2QFY16 Result Review (Wholly owned subsidiary of Bank of Baroda) HOLD PI Industries Ltd. Custom synthesis

More information

CMP: 1152.10 JUNE 2016 SWARAJ ENGINES LTD

CMP: 1152.10 JUNE 2016 SWARAJ ENGINES LTD Index Details SWARAJ ENGINES LTD Result Update (PARENT BASIS): Q4 FY16 Stock Data Sector Auto Parts & Equipment BSE Code 500407 Face Value 10.00 52wk. High / Low (Rs.) 1207.90/762.00 Volume (2wk. Avg.)

More information

Tree House Education & Accessories

Tree House Education & Accessories 2QFY2016 Result Update Educational Services November 10, 2015 Tree House Education & Accessories Performance Highlights Y/E March (` cr) 2QFY16 2QFY15 % chg (qoq) 1QFY16 % chg (yoy) Net sales 57 50 15.1

More information

Mangalam Cement Weak volumes marred performance

Mangalam Cement Weak volumes marred performance CMP* (Rs) 206 Market Cap. (Rs bn) 5.5 Free Float (%) 72 Shares O/S (mn) 26.7 Mangalam Cement Weak volumes marred performance Mangalam Cement (MCL) delivered a weak performance in 2Q but was marginally

More information

Navin Fluorine International

Navin Fluorine International RESULTS REVIEW 2QFY16 29 OCT 2015 Navin Fluorine International INDUSTRY CHEMICALS CMP (as on 29 Oct 2015) Rs 1,579 Target Price Rs 1,800 Nifty 8,112 Sensex 26,838 KEY STOCK DATA Bloomberg NFIL IN No. of

More information

Maruti Suzuki. Source: Company Data; PL Research

Maruti Suzuki. Source: Company Data; PL Research Q3 results subdued, Outlook remains good; BUY January 28, 2016 Rohan Korde rohankorde@plindia.com +91 22 66322235 Rating BUY Price Rs4,103 Target Price Rs4,844 Implied Upside 18.1% Sensex 24,470 Nifty

More information

PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)

PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%) BUY CMP 514.75 Target Price 590.00 DOC CODE: FOTL_090220164_3 IGARASHI MOTORS INDIA LTD Result Update (PARENT BASIS): Q3 FY16 FEBRUARY 9 th 2016 ISIN: INE188B01013 12 th h, 2013 Index Details Stock Data

More information

Simplex Infrastructures

Simplex Infrastructures 2QFY216 Result Update Infrastructure November 17, 215 Simplex Infrastructures Performance Highlights Quarterly highlights - Standalone Y/E March (` cr) 2QFY16 1QFY16 2QFY15 % chg (yoy) % chg (qoq) Net

More information

SUPREME INDUSTRIES LTD Plastic Products HOLD RETAIL EQUITY RESEARCH

SUPREME INDUSTRIES LTD Plastic Products HOLD RETAIL EQUITY RESEARCH Q2FY16 RESULT UPDATE GEOJIT BNP PARIBAS Research RETAIL EQUITY RESEARCH SUPREME INDUSTRIES LTD Plastic Products BSE CODE:509930 NSE CODE: SUPREMEIND Bloomberg CODE: SIL IN SENSEX: 24,470 HOLD CMP Rs725

More information

GAIL (India) Ltd. INR 346

GAIL (India) Ltd. INR 346 Feb-15 Apr-15 Jun-15 Aug-15 Oct-15 Dec-15 Feb-16 India Equity Institutional Research Oil & Gas RESULT UPDATE GAIL (India) Ltd. INR 346 Good performance; Near term outlook looks stable BUY GAIL reported

More information

Polaris BUY. Virtusa acquires majority in Polaris. Institutional Equity Research. November 05, 2015. Target Price Rs220. IT India.

Polaris BUY. Virtusa acquires majority in Polaris. Institutional Equity Research. November 05, 2015. Target Price Rs220. IT India. CMP* (Rs) 204 Market Cap. (Rs bn) 20 Free Float (%) 71 Shares O/S (mn) 100 Polaris Virtusa acquires majority in Polaris Virtusa Corp has purchased promoter and Citi s stake in Polaris of 53% for Rs220

More information

Minda Industries Ltd. INR 886

Minda Industries Ltd. INR 886 Jan-15 Mar-15 May-15 Jul-15 Sep-15 Nov-15 Jan-16 India Equity Institutional Research Automobiles RESULT UPDATE Minda Industries Ltd. INR 886 Profit boosted by margins ACCUMULATE In Q3FY16, Minda Industries

More information

Strong operational performance

Strong operational performance ABB India Equity Research Engineering & Capital Goods February 8, 2016 Result Update Emkay Your success is our success Strong operational performance CMP Target Price Rs1,134 Rs1,407 ( ) Rating Upside

More information

MAITHAN ALLOYS LTD Result Update (PARENT BASIS): Q4 FY16

MAITHAN ALLOYS LTD Result Update (PARENT BASIS): Q4 FY16 Index Details MAITHAN ALLOYS LTD Result Update (PARENT BASIS): Q4 FY16 Stock Data Sector Iron & Steel/Interm. Products BSE Code 590078 Face Value 10.00 52wk. High / Low (Rs.) 313.80/72.25 Volume (2wk.

More information

www.pvpglobal.com SECTOR: REALTY REPORTING DATE: 31 ST MAY, 2016 PVP Ventures Ltd

www.pvpglobal.com SECTOR: REALTY REPORTING DATE: 31 ST MAY, 2016 PVP Ventures Ltd 31 st May, 2016 TABLE 1 MARKET DATA (STANDALONE) (As on 31 st May, 2016) NSE Code PVP NSE Market Price ( ) 4.50 NSE Market Cap. ( Cr.) 118.85 Sector Realty Face Value ( ) 10.00 Equity ( Cr.) 245.05 52

More information

RamKrishna Forgings Ltd.

RamKrishna Forgings Ltd. January 3, 2014 RamKrishna Forgings Ltd. Poised for Growth CMP INR 81 Target INR 117.2 Coverage Follow Up BUY Key Share Data Face Value (INR) 10 Equity Capital (in INR Million) 211.0 Market Cap (in INR

More information

RAJESH EXPORTS LIMITED GLOBAL PRESENCE IN GOLD AND GOLD PRODUCTS. Earnings Presentation Q2 FY16

RAJESH EXPORTS LIMITED GLOBAL PRESENCE IN GOLD AND GOLD PRODUCTS. Earnings Presentation Q2 FY16 RAJESH EXPORTS LIMITED GLOBAL PRESENCE IN GOLD AND GOLD PRODUCTS Earnings Presentation Q2 FY16 Company Overview COMPANY OVERVIEW Rajesh Exports Ltd. (REL) was incorporated in 1989. Currently REL is a leader

More information

Company Overview. Industry Overview. Financial Performance

Company Overview. Industry Overview. Financial Performance Jan/15 Feb/15 Mar/15 Apr/15 May/15 Jun/15 Jul/15 Aug/15 Sep/15 Oct/15 Nov/15 Dec/15 Trident Limited CMP: 52.70 January 13, 2016 Stock Details BSE code 521064 BSE ID TRIDENT Face value ( ) 10 No of shares

More information

Britannia Industries

Britannia Industries Rally in Input costs near term drag, Maintain BUY June 20, 2016 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Gaurav Jogani gauravjogani@plindia.com +91 22 66322238 Rating BUY Price Rs2,641

More information

Just Dial Ltd Bloomberg Code: JUST IN

Just Dial Ltd Bloomberg Code: JUST IN Communications - Internet Media Oct 14, 215 Bloomberg Code: JUST IN India Research - Stock Broking India s local search engine, warming up with add-on services Just Dial is now into a platform where people

More information

Bharat Electronics. Strong margins, improved inflows! Source: Company Data; PL Research

Bharat Electronics. Strong margins, improved inflows! Source: Company Data; PL Research Strong margins, improved inflows! January 28, 2016 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Samir Bendre samirbendre@plindia.com +91 22 66322256 Rating Accumulate Price Rs1,228 Target Price Rs1,353

More information

Granules India Ltd. INR 113

Granules India Ltd. INR 113 India Equity Institutional Research Pharma RESULT UPDATE Granules India Ltd. INR 113 Misses expectation BUY Result highlights Net sales for the quarter grew by a moderate 8% YoY to INR 3,449mn below our

More information

Pidilite Industries. Source: Company Data; PL Research

Pidilite Industries. Source: Company Data; PL Research Bountiful margin expansion in a tepid demand scenario February 03, 2016 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Gaurav Jogani gauravjogani@plindia.com +91 22 66322238 Rating Accumulate

More information

MBL Infrastructure Ltd

MBL Infrastructure Ltd Q4FY11 First Cut Enhancing investment decisions Explanation of CRISIL Fundamental and Valuation (CFV) matrix The CFV Matrix (CRISIL Fundamental and Valuation Matrix) addresses the two important analysis

More information

The Ramco Cements. Source: Company Data; PL Research

The Ramco Cements. Source: Company Data; PL Research Robust performance; remains the best play on Southern region February 09, 2016 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Ankit Shah ankitshah@plindia.com +91 22 66322244 Rating BUY Price

More information

HCC BUY. Infrastructure January 29, 2016

HCC BUY. Infrastructure January 29, 2016 Jan-15 Mar-15 Apr-15 May-15 Jul-15 Aug-15 Sep-15 Nov-15 Dec-15 Jan-16 India Research Infrastructure January 29, 2016 QUARTERLY REVIEW Bloomberg: IN Reuters: HCNS.BO BUY Better margins drive earnings s

More information

Kotak Mahindra Bank Rs 685

Kotak Mahindra Bank Rs 685 India Equity Institutional Research BANKS RESULT UPDATE Kotak Mahindra Bank Rs 685 Smooth merger; benefits to accrue HOLD KMB s consolidated PAT for Q4FY15 stood at INR 9.5 that primarily on the back of

More information

BUY. JYOTHY LABORATORIES LTD Result Update (CONSOLIDATED BASIS): Q2 FY16. CMP 298.00 Target Price 340.00. DECEMBER 29 th 2015.

BUY. JYOTHY LABORATORIES LTD Result Update (CONSOLIDATED BASIS): Q2 FY16. CMP 298.00 Target Price 340.00. DECEMBER 29 th 2015. BUY CMP 298.00 Target Price 340.00 JYOTHY LABORATORIES LTD Result Update (CONSOLIDATED BASIS): Q2 FY16 DECEMBER 29 th 2015 ISIN: INE668F01031 12 th h, 2013 Index Details Stock Data Sector Household Products

More information

Accumulate. Exide Industries Ltd(EIL) Automobile Ancillaries RETAIL EQUITY RESEARCH

Accumulate. Exide Industries Ltd(EIL) Automobile Ancillaries RETAIL EQUITY RESEARCH Q3FY16 RESULT UPDATE GEOJIT BNP PARIBAS Research RETAIL EQUITY RESEARCH Exide Industries Ltd(EIL) Automobile Ancillaries BSE CODE: 500086 NSE CODE: EXIDEIND Bloomberg CODE: EXID IN SENSEX: 23,759 Accumulate

More information

Salzer Electronics. 2QFY16 Result Review BUY. Steady performance continued; maintain BUY. Sector: Electric Equipment

Salzer Electronics. 2QFY16 Result Review BUY. Steady performance continued; maintain BUY. Sector: Electric Equipment $CompanyN ame$ Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 Nov-15 2QFY16 Result Review (Wholly owned subsidiary of Bank of Baroda) BUY Salzer Electronics Ltd. Steady

More information

JSW Energy Ltd. Interest expenses dragged the bottom-line BUY. Jan. 25, 2016

JSW Energy Ltd. Interest expenses dragged the bottom-line BUY. Jan. 25, 2016 JSW Energy Ltd. Interest expenses dragged the bottom-line JSW Energy Ltd. (JSWEL) reported a mixed set of numbers for Q3 FY16 quarter. The company reported a consolidated total operating income of Rs.

More information

Initial Public Offer Review

Initial Public Offer Review IPO RECOMMENDATION: SUBSCRIBE IN SUMMARY We like the JUST DIAL business model and would have recommended a Strong Buy if the valuations were a tad lower. However, considering no existing investor would

More information

GlaxoSmithKline Consumer Healthcare

GlaxoSmithKline Consumer Healthcare Strong pricing power, Attractive valuations "BUY" February 09, 2016 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Gaurav Jogani gauravjogani@plindia.com +91 22 66322238 Rating BUY Price Rs5,837

More information

Graphite Electrodes. Imposition of antidumping duty augurs well. Sector Update. ICICI Securities Ltd Retail Equity Research.

Graphite Electrodes. Imposition of antidumping duty augurs well. Sector Update. ICICI Securities Ltd Retail Equity Research. Sector Update Rating matrix Target price Company Old New CMP Potential Upside HEG 225 275 238 19% Graphite India 85 15 91 18% Target period 12-15 months Price performance (%) Return % 1M 3M 6M 12M HEG

More information

UltraTech Cement Ltd.

UltraTech Cement Ltd. Oct-11 Nov-11 Dec-11 Jan-12 Feb-12 Mar-12 Apr-12 May-12 Jun-12 Jul-12 Aug-12 Sep-12 Oct-12 October 31, 212 COMPANY RESULTS REPORT REVIEW UltraTech Cement Ltd. Rich valuation overlooks strong performance

More information

Indian Overseas Bank Limited

Indian Overseas Bank Limited Vol. 03/09-10 June 27, 2009 Analyst: Abhishek Gupta abhishekg@bajajcapital.com Reviewed by: Alok Agarwala aloka@bajajcapital.com B U Y CMP (26.06.09) : Rs. 85.90 Target : Rs. 125.00 Upside Potential :

More information

East India Hotels (EIH) Ltd Growing Strategically

East India Hotels (EIH) Ltd Growing Strategically East India Hotels (EIH) Ltd Growing Strategically BSE Code 500840 NSE Code EIHOTEL Bloomberg Code EIH@IN Face Value 10 CMP Rs 224 Market Cap Rs 11.7bn (as on August 27th 2004) Share Holding Pattern Others

More information

HINDUSTAN COMPOSITES LTD Result Update (PARENT BASIS): Q4 FY16

HINDUSTAN COMPOSITES LTD Result Update (PARENT BASIS): Q4 FY16 HINDUSTAN COMPOSITES LTD Result Update (PARENT BASIS): Q4 FY16 Index Details Stock Data Sector Auto Parts & Equipment BSE Code 509635 Face Value 10.00 52wk. High / Low (Rs.) 1567.00/750.00 Volume (2wk.

More information

SREI Infrastructure Ltd.

SREI Infrastructure Ltd. Report Date 22nd Oct, 2010 Company Name SREI Infrastructure Ltd. Price / Recommendation CMP: - `121 Buy (Medium Risk Medium Return) Company Background SREI Infrastructure Finance Ltd started its operations

More information

Cipla Ltd. Rs. 741. India Equity Institutional Research Pharma. One off revenues from Nexium supply drives earnings HOLD. Target Price (Rs): 765

Cipla Ltd. Rs. 741. India Equity Institutional Research Pharma. One off revenues from Nexium supply drives earnings HOLD. Target Price (Rs): 765 India Equity Institutional Research Pharma RESULT UPDATE Cipla Ltd. Rs. 741 One off revenues from Nexium supply drives earnings HOLD Result highlights Cipla s Q1FY16 result beats our estimates due to higher

More information

DISCUSSION SUMMARY. Q3 & 9M FY16 Results Highlights. Consolidated Financials. About Us. Business Strategy & Outlook

DISCUSSION SUMMARY. Q3 & 9M FY16 Results Highlights. Consolidated Financials. About Us. Business Strategy & Outlook DISHMAN PHARMACEUTICALS & CHEMICALS LIMITED Q3 & 9M FY16 RESULTS UPDATE FEBRUARY 2016 DISCUSSION SUMMARY Q3 & 9M FY16 Results Highlights Consolidated Financials About Us Business Strategy & Outlook 2 SAFE

More information

Mphasis. FY17 could be a year of revenue growth. Source: Company Data; PL Research

Mphasis. FY17 could be a year of revenue growth. Source: Company Data; PL Research FY17 could be a year of revenue growth February 08, 2016 Govind Agarwal govindagarwal@plindia.com +91 22 66322300 Rating Accumulate Price Rs440 Target Price Rs510 Implied Upside 15.9% Sensex 24,617 Nifty

More information

Shiva Global Agro Industries Limited

Shiva Global Agro Industries Limited 19 January 2016 CMP: Rs.21.7 Industry: Chemicals BSE Group/Index: XD Promoters Gilda and Agrawal family Year of incorporation 1993 Registered office Shri Hanuman Nagar, Osman Nagar Road, Village Dhakni,

More information

Bharat Petroleum Corporation Ltd

Bharat Petroleum Corporation Ltd Bharat Petroleum Corporation Ltd Sector: Refineries/Petro-Products/PSU BSE/NSE: 500547/BPCL - EQ Index: BSE 100/Nifty 50 Meeting Type: Postal Ballot Announcement Date: 19 December 2011 Proxy Deadline:19

More information

DATRON AG. Investor day supports our positive view. Buy (Buy) 12.50 EUR (12.50 EUR ) BANKHAUS LAMPE // 1 17/09/2015

DATRON AG. Investor day supports our positive view. Buy (Buy) 12.50 EUR (12.50 EUR ) BANKHAUS LAMPE // 1 17/09/2015 BANKHAUS LAMPE // 1 DATRON AG Investor day supports our positive view 17/09/2015 Buy (Buy) 12.50 EUR (12.50 EUR ) Close 15/09/2015 9.75 EUR Bloomberg: DAR GY WKN: A0V9LA Sector Engineering Share price

More information

Bharat Earth Movers (BEML)

Bharat Earth Movers (BEML) 2QFY2016 Result Update Capital Goods November 13, 2015 Bharat Earth Movers (BEML) Performance Highlights Quarterly highlights - Standalone Y/E March (` cr) 2QFY16 1QFY16 2QFY15 % chg (yoy) % chg (qoq)

More information

CD Equisearch Pvt Ltd

CD Equisearch Pvt Ltd Dec 10, 2015 Mayur Uniquoters Ltd. No. of shares (m) 46.3 Mkt cap (Rs crs/$m) 1943/291 Current price (Rs/$) 420/6.3 Price target (Rs/$) 475/7.1 52 week H/L (Rs.) 518/378 Book Value (Rs/$) 67.8/1.0 P/BV

More information

OptimizeRx OPRX. Buy. Platform Potential Continues to Grow $0.87 $4.00. Refer to the last two pages of this report for Disclosures

OptimizeRx OPRX. Buy. Platform Potential Continues to Grow $0.87 $4.00. Refer to the last two pages of this report for Disclosures Nov 14, 2014 Healthcare OptimizeRx Platform Potential Continues to Grow Other OTC OPRX Buy Rating Unchanged Current Price $0.87 Target Price $4.00 Market Capitalization 20.32M Shares Outstanding 23.36M

More information

Share gains with healthy margin uptick; Retain Buy

Share gains with healthy margin uptick; Retain Buy Colgate-Palmolive India Equity Research Consumers January 23, 2015 Result Update Emkay Your success is our success Share gains with healthy margin uptick; Retain Buy CMP Target Price Rs1,913 Rs1,940 (

More information

ZetaDisplay. Europe leads the way. EPaccess

ZetaDisplay. Europe leads the way. EPaccess EPaccess Media Sweden 22 November 213 Equity Research +46 8 463 8 analys@penser.se ZetaDisplay Europe leads the way Risk and Return Potential Return Potential Risk High High Risk Current Price 4,8 High/Low

More information

Staying Agile Surging Ahead

Staying Agile Surging Ahead SAP ENTERPRISE SUPPORT Staying Agile Surging Ahead for the quarter ending 31 st December, 2010 February 3, 2011 Omnitech DR BCP Consulting Services Agenda Company Overview Financial Management s View Key

More information

Independent Equity Research ACCENTIA TECHNOLOGIES LTD ACCENTIA TECHNOLOGIES LIMITED IT/ ITES: BUSINESS PROCESSING OUTSOURCING BSE Scrip Code: 531897

Independent Equity Research ACCENTIA TECHNOLOGIES LTD ACCENTIA TECHNOLOGIES LIMITED IT/ ITES: BUSINESS PROCESSING OUTSOURCING BSE Scrip Code: 531897 CARE Independent Equity Research ACCENTIA TECHNOLOGIES LTD ACCENTIA TECHNOLOGIES LIMITED IT/ ITES: BUSINESS PROCESSING OUTSOURCING BSE Scrip Code: 531897 CMP -159.50 1 9 th Dec 2010 Leading player in healthcare

More information

IFGL REFRACTORIES LTD. RESULT UPDATE PRESENTATION, February 2016

IFGL REFRACTORIES LTD. RESULT UPDATE PRESENTATION, February 2016 IFGL REFRACTORIES LTD RESULT UPDATE PRESENTATION, February 2016 Safe Harbor This presentation and the accompanying slides (the Presentation ), has been prepared by IFGL Refractories Limited (the Company

More information

Butterfly Gandhimathi (GANAP) 188

Butterfly Gandhimathi (GANAP) 188 Result Update Rating matrix Rating : Buy Target : 240 Target Period : 12 months Potential Upside : 27% What s changed? Target EPS FY16E EPS FY17E Rating Quarterly performance Unchanged Unchanged Unchanged

More information

Software Testing Market India

Software Testing Market India Software Testing Market India July 2014 Executive Summary Market Software Testing market in India was valued at ~ INR xx bn in 20-- and is projected to grow at a CAGR of ~ x1% between 20--- and 20-- Over

More information

PRESS RELEASE Noida, Tuesday, February 9, 2016 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q3 & 9M FY2016 RESULTS JUBILANT

More information

ICICI Securities Limited BPCL (BHAPET) Subsidy burden drags bottomline in the red. Result Update. Valuation WHAT S CHANGED.

ICICI Securities Limited BPCL (BHAPET) Subsidy burden drags bottomline in the red. Result Update. Valuation WHAT S CHANGED. Result Update Rating matrix Rating : Hold Target : 727 Target Period : 12-15 months Potential Upside : 6% Key Financials ( Crore) FY1 FY11E FY12E FY13E Revenues 122359.9 151625.2 186429.1 183147.7 EBITDA

More information

Khambatta Securities Ltd.

Khambatta Securities Ltd. Attractive Valuation Strong Buy Sector : Bank Private Target Price : Rs 284 Current Market Price : Rs 230 Market Cap : Rs 1,337 bn 52-week High/Low : Rs 393/216 Daily Avg. Volume : 13.88 mn Shares in issue

More information

Jubilant Life Sciences

Jubilant Life Sciences Radiopharma, Niacin continues to drive sales, margins October 30, 2015 Surajit Pal surajitpal@plindia.com +912266322259 Rating BUY Price Rs401 Target Price Rs578 Implied Upside 44.1% Sensex 26,838 Nifty

More information

Axis Bank. Strong core performance. Source: Company Data; PL Research

Axis Bank. Strong core performance. Source: Company Data; PL Research Strong core performance January 17, 2011 Abhijit Majumder abhijitmajumder@plindia.com +91 22 66322236 Umang Shah umangshah@plindia.com +91 22 66322242 Rating BUY Price Rs1,230 Target Price Rs1,600 Implied

More information

On the right track. Source: Company Data; PL Research

On the right track. Source: Company Data; PL Research On the right track December 09, 2013 Balwindar Singh balwindarsingh@plindia.com +912266322239 Rating BUY Price Rs170 Target Price Rs210 Implied Upside 23.5% Sensex 20,997 Nifty 6,260 (Prices as on December

More information

EQLine Research and Services Pvt Ltd. yoy (%) 2QFY16 (27.0) 70,901 41.3 16.7 8,045 30.8. 531bp 7,290. 736bp 11.3 6,720 38.

EQLine Research and Services Pvt Ltd. yoy (%) 2QFY16 (27.0) 70,901 41.3 16.7 8,045 30.8. 531bp 7,290. 736bp 11.3 6,720 38. 3QFY216 Result Update Oil & Gas Reliance Industries ACCUMULATE Performance highlights CMP Target Price Consolidated (Rs cr) 3QFY16 3QFY15 yoy (%) 2QFY16 qoq% Net revenue 68,261 93,528 (27.) 7,91 (3.7)

More information

Un-audited Consolidated Financials Results for the Quarter ended 30th September 2015.

Un-audited Consolidated Financials Results for the Quarter ended 30th September 2015. 8K MILES SOFTWARE SERVICES LTD Un-audited Consolidated Financials Results for the Quarter ended 30th September 2015. I For the Quarter Ended Rupees in Lakhs Year ended 30-Sep-15 30-Jun-15 30-Sep-14 31-Mar-15

More information

JCT Limited. Stock Performance Details Shareholding Details September 2015

JCT Limited. Stock Performance Details Shareholding Details September 2015 JCT Limited Date: 17 th February, 216 Stock Performance Details Shareholding Details September 215 Current Price : ` 5.49^ Face Value : ` 2.5 per share 52 wk High / Low : ` 1.99 / 2.55 Total Traded Volume

More information

www.3i infotech.com SECTOR: IT SOFTWARE REPORTING DATE: 31 ST MAY, 2016 3i Infotech Ltd.

www.3i infotech.com SECTOR: IT SOFTWARE REPORTING DATE: 31 ST MAY, 2016 3i Infotech Ltd. 3i Infotech Ltd. 31 st May, 2016 TABLE 1 MARKET DATA (STANDALONE) (As on 31 st May, 2016) NSE Code 3IINFOTECH NSE Market Price ( ) 3.85 NSE Market Cap. ( Cr.) 255.04 Sector IT Software Face Value ( ) 10.00

More information

Agrium Inc. - Company Profile, SWOT & Financial Report

Agrium Inc. - Company Profile, SWOT & Financial Report - Company Profile, SWOT & Financial Report ICD Research. This product is licensed and not to be photocopied _ TABLE OF CONTENTS 1 Agrium Inc. - Key Employees... 7 2 Agrium Inc. - Key Employee Biographies...

More information

Techno Electric & Engineering Limited

Techno Electric & Engineering Limited Engineering & Capital Goods Event Update Techno Electric & Engineering Limited Buy Wind business spin off will lead to value unlocking. Institutional Research CMP (`) 404 Target (`) 504 Nifty: 8,224 Sensex:

More information

HOLD. The case of missing sales growth ZYDUS WELLNESS. Target Price: Rs 780. Q3highlights

HOLD. The case of missing sales growth ZYDUS WELLNESS. Target Price: Rs 780. Q3highlights The case of missing sales growth Zydus Q3 net sales at Rs1.1 bn was up 3% on a like-to-like basis (Q3 15 had Rs 223 mn additional excise duty credit from prior periods), below our estimate of 6%. The company

More information

Emkay. Revenues traction improves; Retain BUY HSIL. Healthy revenue performance; miss on margins

Emkay. Revenues traction improves; Retain BUY HSIL. Healthy revenue performance; miss on margins HSIL India Equity Research Others February 3, 2016 Result Update Emkay Your success is our success Revenues traction improves; Retain BUY CMP Target Price Rs271 Rs370 ( ) Rating Upside BUY ( ) 36.6 % Healthy

More information

Reliance Industries. (CMP/TP: `732/1,006) (Buying Range: `732 to `747)

Reliance Industries. (CMP/TP: `732/1,006) (Buying Range: `732 to `747) (CMP/TP: `732/1,006) (Buying Range: `732 to `747) Core business margins to stabilise: RIL reported robust refining margins of US$10.2/bbl in 1HFY2012. However, during 3QFY2012, Singapore gross refining

More information

BUY. Muted Q3; Brands & Retail story to unfold ARVIND. Target Price: Rs 344. Segmental highlights

BUY. Muted Q3; Brands & Retail story to unfold ARVIND. Target Price: Rs 344. Segmental highlights 05 FEB 2016 Quarterly Update BUY Target Price: Rs 344 Muted Q3; Brands & Retail story to unfold Arvind s Q3 consolidated revenue at Rs 21.6 bn (Rs 20.7 bn in Q3FY15) was marginally below our estimate of

More information

AXIS BANK LTD. Company Details : Company Profile: Investment Rationale: Share Holding Pattern (%) Snapshot as on 30th June 2014:

AXIS BANK LTD. Company Details : Company Profile: Investment Rationale: Share Holding Pattern (%) Snapshot as on 30th June 2014: Date: September 22 nd 2014 Company Details : CMP(`) 407 NSE Symbol AXISBANK BSE Code 532215 Face Value (`) 2.00 Dividend Yield (%) 1.00 Book Value 170 Market Cap (Cr) 94,800 EPS - TTM (`): 27.6 P/E Ratio

More information

Coal India Ltd. Subdued e-auction realization impacted profitability BUY. Nov. 17, 2015

Coal India Ltd. Subdued e-auction realization impacted profitability BUY. Nov. 17, 2015 17-Nov-14 17-Dec-14 17-Jan-15 17-Feb-15 17-Mar-15 17-Apr-15 17-May-15 17-Jun-15 17-Jul-15 17-Aug-15 17-Sep-15 17-Oct-15 Coal India Ltd. Subdued e-auction realization impacted profitability Coal India Ltd.

More information

Results impacted by subdued demand

Results impacted by subdued demand India Equity Research Agri Input & Chemicals January 25, 2016 Result Update Coromandel International Results impacted by subdued demand Emkay Your success is our success CMP Target Price Rs165 Rs225 (

More information

Cipla Ltd. INR 542. India Equity Institutional Research Pharma. Muted quarter; outlook remains robust. Target Price (INR): 646. Potential Upside : 19%

Cipla Ltd. INR 542. India Equity Institutional Research Pharma. Muted quarter; outlook remains robust. Target Price (INR): 646. Potential Upside : 19% India Equity Institutional Research Pharma RESULT UPDATE Cipla Ltd. INR 542 Muted quarter; outlook remains robust BUY Result highlights Cipla s Q3FY16 Net Sales, EBITDA and PAT were below our estimates.

More information

Cloud Computing Market India

Cloud Computing Market India Cloud Computing Market India October 2014 Executive Summary Market Overview In, overall value of cloud computing services in India was INR x1, being largely driven by factors such as scalability, flexibility

More information

BDI BioEnergy Intern. 20.0 Neutral. Activity level in Q3 might not support FY estimates

BDI BioEnergy Intern. 20.0 Neutral. Activity level in Q3 might not support FY estimates 8/11/1 8/1/11 8/3/11 8/5/11 8/7/11 8/9/11 8/11/11 8/1/12 8/3/12 8/5/12 8/7/12 8/9/12 MATELAN Research Preview Note Price as of 9/11/12: 8.69 12 November 212 Company / Sector Fair Value Recommendation BDI

More information

Adani Power Ltd. August 10 th, 2015 CMP (`) 28. Key Developments

Adani Power Ltd. August 10 th, 2015 CMP (`) 28. Key Developments Jul-14 Aug-14 Sep-14 Oct-14 Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 s. Adani Power Ltd.. August 10 th, 2015 BSE Code: 533096 NSE Code: ADANIPOWER Reuters Code: ADAN.NS Bloomberg Code: ADANI:IN

More information

GlaxoSmithKline Pharma

GlaxoSmithKline Pharma 2QFY2016 Result Update Pharmaceutical November 2, 2015 GlaxoSmithKline Pharma Performance Highlights Y/E Mar (` cr) 2QFY2016 1QFY2016 % chg (qoq) 2QFY2015 % chg (yoy) Net Sales 692 622 11.3 739 (6.4) Other

More information

Va Tech Wabag. Source: Company Data; PL Research

Va Tech Wabag. Source: Company Data; PL Research Weak execution, guidance hints a strong Q4FY16 February 08, 2016 Nishna Biyani nishnabiyani@plindia.com +91 22 66322239 Keyur Pandya keyurpandya@plindia.com +91 22 +91 22 66322247 Rating BUY Price Rs577

More information

PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)

PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%) BUY CMP 1077.50 Target Price 1200.00 BHARAT RASAYAN LTD Result Update (PARENT BASIS): Q2 FY16 DECEMBER 7 th 2015 ISIN: INE838B01013 12 th h, 2013 Index Details Stock Data Sector Agrochemicals BSE Code

More information

Firstsource Solutions (FIRSOU) 31

Firstsource Solutions (FIRSOU) 31 Result Update Rating matrix Rating : Buy Target : 45 Target Period : 12 months Potential Upside : 45% What s changed? Target EPS FY16E EPS FY17E Rating Unchanged Unchanged Unchanged Unchanged Quarterly

More information

HCL Technologies BUY. Performance Highlights CMP. `857 Target Price `1,132. 1QFY2016 Result Update IT. 3-year price chart

HCL Technologies BUY. Performance Highlights CMP. `857 Target Price `1,132. 1QFY2016 Result Update IT. 3-year price chart 1QFY2016 Result Update IT October 21, 2015 HCL Technologies Performance Highlights (` cr) Consl. 1QFY16 4QFY15 % chg (qoq) 1QFY15 % chg (yoy) Net revenue 10,097 9,777 3.3 8,735 15.6 EBIT 1,979 1,976 0.2

More information

SAIL (SAIL) 56. Dismal performance. Result Update. ICICI Securities Ltd Retail Equity Research. August 17, 2015

SAIL (SAIL) 56. Dismal performance. Result Update. ICICI Securities Ltd Retail Equity Research. August 17, 2015 Result Update Rating matrix Rating : Sell Target : 50 Target Period : 12 months Potential Upside : -11% What s Changed? Target Changed from 60 to 50 EPS FY16E Changed from 4.8 to 1.1 EPS FY17E Changed

More information

Indo Count Industries Ltd (INDCOU)

Indo Count Industries Ltd (INDCOU) Management Meet Note Rating Matrix Rating : Unrated Target : NA Target Period : NA Potential Upside : NA Key Financials ( Crore) FY11 FY12 FY13 FY14 FY15 Net Sales 708.2 779.7 1,186.8 1,467.6 1716.9 EBITDA

More information

Bharatiya Global Infomedia Ltd

Bharatiya Global Infomedia Ltd Bharatiya Global Infomedia Ltd 31 st May, 2016 TABLE 1 MARKET DATA (STANDALONE) (As on 31 st May, 2016) NSE Code BGLOBAL NSE Market Price ( ) 5.70 NSE Market Cap. ( Cr.) 9.25 Sector IT Software Face Value

More information

FY08 FY09 FY10 FY11E FY12E FY13E FY14E FY15E

FY08 FY09 FY10 FY11E FY12E FY13E FY14E FY15E XYZ Company Limited Date Valuation Report: DUMMY Executive Summary INDUSTRY: XX XYZ Company Limited (hereinafter referred to as XYZ or the company ) is a XX manufacturing company and markets its products

More information

Sundaram Finance. Target price (INR) 452 Momentum in loans sustains, upgrade to Hold

Sundaram Finance. Target price (INR) 452 Momentum in loans sustains, upgrade to Hold HOLD Target price (INR) 452 Momentum in loans sustains, upgrade to Hold India Equity Research Financials January 30, 2013 Rating The higher than expected growth in the NII was driven by an improvement

More information

HOLD ASTRAL POLYTECHNIK. Q3 muted; recovery ahead. Target Price: Rs 377. Key highlights. Key drivers

HOLD ASTRAL POLYTECHNIK. Q3 muted; recovery ahead. Target Price: Rs 377. Key highlights. Key drivers 11 FEB 2016 Quarterly Update HOLD Target Price: Rs 377 Q3 muted; recovery ahead Astral sq3fy16 results were impacted due to: (1) adverse raw-material prices in pipe division (~Rs 80 mn), (2) closure of

More information